Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) has announced an upcoming investor webcast scheduled for Thursday, May 15, 2025, at 4:15 PM Eastern Time. The company will use this webcast to review its first-quarter 2025 financial results and provide corporate updates. The company plans to file its Form 10-Q earnings report for the quarter ended March 31, 2025, on May 15, 2025.
Jaguar Health announced promising proof-of-concept results for their drug crofelemer in treating rare intestinal diseases. The study showed crofelemer reduced total parenteral nutrition (TPN) requirements by up to 27% in patients with Microvillus Inclusion Disease (MVID) and by 12.5% in those with Short Bowel Syndrome (SBS-IF).
The trial, presented at the Annual ELITE PED-GI Congress, demonstrated reduced stool volume output and increased urine output, indicating improved nutrient absorption. Dr. Mohamad Miqdady, Chief of Pediatric Gastroenterology at Sheikh Khalifa Medical City, led this open-label study of crofelemer's novel liquid formulation.
Notably, when a pediatric MVID patient discontinued crofelemer after 12 weeks, symptoms worsened within 8 days, leading to treatment reinstatement. The company is pursuing expedited regulatory pathways through EMA's PRIME program and FDA's Breakthrough Therapies program, given the significant unmet need in treating these rare conditions.
Jaguar Health has announced an upcoming investor webcast on April 30, 2025, at 8:30 AM Eastern to present initial results from a proof-of-concept study of crofelemer. The study focuses on two rare diseases: Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF).
The data was recently presented by Dr. Mohamad Miqdady at the 11th Annual ELITE PED-GI Congress in Abu Dhabi. The webcast will cover:
- Patient experience with MVID and SBS-IF
- Impact of crofelemer on disease progression
- Quality of life improvements
- Potential expedited regulatory pathways for MVID treatment
Notably, MVID is an ultrarare pediatric condition characterized by severe diarrhea and malabsorption, currently with no approved drug treatments. The study utilizes a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug.
Jaguar Health (NASDAQ:JAGX) has announced an upcoming investor webcast on April 30, 2025, to present initial results from a proof-of-concept study of crofelemer, their plant-based anti-secretory prescription drug. The study focuses on treating Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF).
The preliminary results were presented by Dr. Mohamad Miqdady at the 11th Annual ELITE PED-GI Congress in Abu Dhabi. The webcast will feature key opinion leaders including Dr. Miqdady, Dr. Christos Tzivinikos, and Dr. Pravin Chaturvedi.
Jaguar is currently conducting multiple studies: three proof-of-concept investigator-initiated trials and two placebo-controlled Phase 2 studies across the United States, European Union, and Middle East/North Africa regions. Additional proof-of-concept results are expected throughout 2025, potentially supporting early patient access to crofelemer in EU countries.
Jaguar Health (NASDAQ:JAGX) announced that preliminary results from an ongoing pediatric trial of crofelemer, their plant-based anti-secretory drug, will be presented at the April 2025 ELITE PED-GI Congress in Abu Dhabi. The study focuses on treating microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).
Crofelemer has received Orphan Drug Designation from both FDA and EMA for these conditions. The proof-of-concept study evaluates crofelemer's potential to improve stool formation, enhance nutrient absorption, and reduce total parenteral nutrition (TPN) needs in patients. Currently, there are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea.
Positive results could potentially qualify crofelemer for the EMA's PRIME program and FDA's Breakthrough Therapies program, expediting development and review processes. The study is being conducted at Sheikh Khalifa Medical City under Dr. Mohamad Miqdady's leadership.
Jaguar Health (NASDAQ:JAGX) announced significant results from their Phase 3 OnTarget study focusing on Mytesi (crofelemer) for cancer therapy-related diarrhea. The study's prespecified subgroup analysis of breast cancer patients showed statistically significant results, despite the trial not meeting its primary endpoint across all tumor types.
The company has secured a Type C Meeting with the FDA in Q2 2025 to discuss potential approval pathways for crofelemer in breast cancer patients. The trial included 183 breast cancer patients out of 287 total participants. The results will be presented at the MASCC Annual Meeting in Seattle (June 26-28, 2025).
Additionally, a second late-breaker abstract on oral mucositis in cancer patients has been accepted for presentation at the same MASCC meeting, highlighting the company's broader focus on cancer supportive care.
Napo Pharmaceuticals, a Jaguar Health company (NASDAQ:JAGX), is showcasing Gelclair, their FDA-approved oral mucositis prescription product, at the Oncology Nursing Society Congress in Denver. Gelclair represents the company's third commercialized prescription product and marks their expansion into cancer-related supportive care.
Gelclair is a protective gel that provides pain relief for oral mucositis ('chemo mouth'), a common side effect affecting up to 40% of chemotherapy patients and 90% of head and neck cancer patients receiving chemo and radiotherapy. The product uniquely offers soothing relief without stinging or burning effects.
The company's core target audiences are head and neck cancer patients (71,110 US cases in 2024) and bone marrow transplant patients (approximately 23,000 annually). Notably, oral mucositis has been identified as the most significant adverse event in oncology by the National Comprehensive Cancer Network task force, with 19% of head and neck cancer patients requiring hospitalization due to high-grade mucositis.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
